Median Technologies to Showcase AI-Powered iCRO Imaging at ASCO 2026
Median Technologies to Present AI-Powered Central Imaging and iCRO Services for Oncology Clinical Trials at ASCO 2026 Annual Meeting Median Technologies, a global leader in AI-powered imaging analytics and central imaging services for oncology clinical trials, has announced its participation…
AHF Ebola Crisis Underscores Breakdown in Global Health Infrastructure
Ebola Crisis Exposes Failures in Global Health Architecture, Says AIDS Healthcare Foundation As Uganda and the Democratic Republic of the Congo (DRC) grapple with a fast-moving Ebola outbreak, the AIDS Healthcare Foundation AIDS Healthcare Foundation (AHF) has warned that the…
JAMA Neurology Publishes Positive Phase 3 Ecopipam Results in Tourette Syndrome
Phase 3 Ecopipam Data Show Sustained Tic Improvement and Delayed Relapse in Tourette Syndrome Newly published Phase 3 clinical trial results in JAMA Neurology demonstrate that ecopipam, an investigational first-in-class dopamine D1 receptor antagonist, significantly delayed time to relapse and…
Octave Bioscience Accelerates Precision Neurology Expansion Through Strategic Leadership Appointment
Octave Bioscience Strengthens Precision Neurology Strategy with Appointment of Zachary Fernandes as Vice President of Business Development Octave Bioscience, a commercial-stage precision medicine company dedicated to advancing biomarker-driven solutions for multiple sclerosis (MS), Parkinson’s disease, and other neurodegenerative disorders, has…
Insulet Issues Voluntary Medical Device Correction Affecting Certain Omnipod® Pods
Insulet Launches Voluntary Medical Device Correction for Certain Omnipod® Pods Due to Potential Insulin Under-Delivery Risk Insulet Corporation, a leading manufacturer of tubeless insulin delivery systems, has announced a voluntary Medical Device Correction affecting specific lots of Omnipod® 5, Omnipod…
Medifast Names Nicholas Johnson as Chief Executive Officer
Medifast Appoints Nicholas Johnson as Chief Executive Officer, Marking a New Chapter in the Company’s Evolution Medifast,the health and wellness company behind the OPTAVIA coach-guided lifestyle platform, has officially appointed Nicholas Johnson as its new Chief Executive Officer, effective June…
Uvalde CISD and Zurn Elkay Partner to Improve Drinking Water Safety
Uvalde CISD and Zurn Elkay Launch Major Initiative to Deliver Cleaner, Safer Drinking Water Thousands of students, teachers, staff members, and community residents in Uvalde will soon have access to cleaner, healthier, and safer drinking water thanks to a significant…
TFG-001 Cell Therapy Shows Promise in Parkinson’s Disease
TreeFrog Therapeutics Unveils Promising Preclinical Data for TFG-001 Cell Therapy in Parkinson’s Disease TreeFrog Therapeutics, a regenerative medicine biotechnology company focused on developing next-generation cell therapies, has announced encouraging new preclinical findings for its lead Parkinson’s disease candidate, TFG-001, ahead…
Florida Lawmakers Strike Deal to Restore HIV Drug Funding
Florida Budget Deal Restores HIV Drug Assistance Program, Reversing Controversial Cuts Thousands of Floridians living with HIV are set to regain access to critical healthcare services after state lawmakers reached a budget agreement that restores funding and eligibility for Florida’s…
Fulgent Announces ASCO 2026 Abstract for FID-007 in Head & Neck Cancer Session
Fulgent Genetics Announces Full Abstract Publication of FID-007 Combination Therapy in Head and Neck Cancer at ASCO 2026 Fulgent Genetics, a technology-driven life sciences company with established laboratory services and an expanding therapeutic development division, announced that the full abstract…
Natera to Present 35 Studies at ASCO, Expanding Leadership in Oncology Clinical Data
Natera to Present 35 Studies at ASCO 2026, Highlighting Expanding Leadership in Oncology and MRD-Guided Cancer Care Natera, a global leader in cell-free DNA and precision medicine, announced a landmark oncology data program for the 2026 American Society of Clinical…
OPTIMA Trial at ASCO Supports Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Veracyte to Present Landmark OPTIMA and ENZAMET Trial Data at ASCO 2026, Strengthening Evidence for Genomic Testing in Breast and Prostate Cancer Care Veracyte, a leading cancer diagnostics company, has announced that new data from two major Phase III clinical…